The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 13, 2024
Filed:
Apr. 11, 2017
Applicant:
Arbutus Biopharma Corporation, Burnaby, CA;
Inventors:
James Heyes, Vancouver, CA;
Richard J. Holland, Vancouver, CA;
Alan D. Martin, Vancouver, CA;
Mark Wood, Port Moody, CA;
Assignee:
ARBUTUS BIOPHARMA CORPORATION, Burnaby, CA;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/54 (2017.01); A61K 31/713 (2006.01); C12N 15/113 (2010.01); A61K 47/60 (2017.01); C07C 237/08 (2006.01); C07H 15/18 (2006.01); C07C 235/10 (2006.01); C07H 15/26 (2006.01); C07J 51/00 (2006.01); C07H 15/08 (2006.01); A61K 47/59 (2017.01); C07J 63/00 (2006.01); C07H 21/00 (2006.01); C07D 211/42 (2006.01); C07D 207/08 (2006.01); C07D 207/12 (2006.01); C12N 15/11 (2006.01); C12N 15/87 (2006.01);
U.S. Cl.
CPC ...
A61K 47/549 (2017.08); A61K 31/713 (2013.01); A61K 47/554 (2017.08); A61K 47/59 (2017.08); A61K 47/60 (2017.08); C07C 235/10 (2013.01); C07C 237/08 (2013.01); C07H 15/08 (2013.01); C07H 15/18 (2013.01); C07H 15/26 (2013.01); C07H 21/00 (2013.01); C07J 51/00 (2013.01); C07J 63/008 (2013.01); C12N 15/113 (2013.01); C07D 207/08 (2013.01); C07D 207/12 (2013.01); C07D 211/42 (2013.01); C12N 15/111 (2013.01); C12N 15/87 (2013.01); C12N 2310/14 (2013.01); C12N 2310/315 (2013.01); C12N 2310/321 (2013.01); C12N 2310/346 (2013.01); C12N 2310/351 (2013.01); C12N 2320/32 (2013.01);
Abstract
The invention provides conjugates that comprise a targeting moiety, a nucleic acid, and optional linking groups as well as synthetic intermediates and synthetic methods useful for preparing the conjugates. The conjugates are useful to target therapeutic nucleic acids to the liver and to treat liver diseases including hepatitis (e.g. hepatitis B and hepatitis D).